These promotional educational meetings have been developed by Soar Beyond and the Bristol Myers Squibb (BMS)/Pfizer Alliance and are fully funded by the BMS/Pfizer Alliance. These online resources have been co-developed by Soar Beyond, the BMS/Pfizer Alliance, and a Clinical Pharmacist and General Practitioner faculty chosen by the BMS/Pfizer Alliance.
This is to be used as a guide only and should be used to augment local guidelines or pathways. Pharmacists are encouraged to link with a GP prescribing/atrial fibrillation lead for supervision and mentorship to support clinical competence.
This digital material is for use by healthcare professionals and is intended to be reviewed online only. Do not distribute. For Prescribing information, click here.
All information provided in this module is for reference only, the latest version of the Summary of Product Characteristics should be consulted when making prescribing decisions.
Adverse events should be reported. Reporting forms and information can be found here, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via [email protected] or 08007311736 (UK).
Job Bag Number: 432UK2001128-03
Date of preparation: November 2020
AF : Atrial Fibrillation
NVAF : Non-Valvular Atrial Fibrilation
0 of 18 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
0 of 18 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
People with atrial fibrillation are how many more times likely to have a stroke?
How many AF-related strokes are there in England daily?
On admission for stroke, how many people with known AF are anticoagulated?
How many lives could be saved in England each year if AF was adequately treated?
What percentage of patients report palpitations as a symptom of AF?
Paroxysmal AF is defined as:
Persistent AF is defined as:
NVAF refers to AF in the absence of a mechanical prosthetic heart valve or moderate to severe mitral stenosis (usually of rheumatoid origin)
An irregular pulse can be detected using pulse palpation
Rate control should be used as a first-line strategy in people with AF that has a reversible cause
Rate control should be used as a first-line strategy in people with new on-set atrial fibrillation
In rate control therapy, what is the treatment aim for heart rate
For patients using a ‘pill in the pocket’ strategy, how often do they take antiarrythmic drugs?
What % of thromboembolic strokes are caused by AF
Following a CHA2DS2-VASc score of 0 in a 54 year old male, what would your treatment option be?
Following a CHA2DS2-VASc score of 1 in a 54 year old male, what would your treatment option be?
Following a CHA2DS2-VASc score of 2 in a 54 year old male, what would your treatment option be?
Patients are considered at high risk of bleeding if they have a HAS-BLED score